Professor Des Richardson
will present a Raine Lecture entitled:
Befriending the lysosome to treat cancer: Therapeutically stabilising MIG6 to degrade EGFR
on Thursday 18 April 2019 at 12.00 – 1.00 pm
at McCusker Auditorium, Harry Perkins Institute of Medical Research
Professor Des Richardson holds the Chair of Cancer Cell Biology at the University of Sydney, Australia, and is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow. He has published 415 articles, reviews, patents, and book chapters over his career with >93% as first, senior or corresponding author (H-index: 85; >30,000 citations over his entire career; with >15,900 citations over the past 5 years and H-index: 57 over the past 5 years). He is Executive Editor of BBA-General Subjects and has served on the Editorial Boards of 43 international journals, including J. Biol. Chem., Antioxidants Redox Signaling, Biochem. J., BBA-Mol Cell Res, Mol. Pharmacol. and Pharmacol. Res.
As a major translational research achievement, he has developed the anti-cancer and anti-metastatic drug, DpC, which overcomes P-glycoprotein-mediated drug resistance and up-regulates the potent metastasis suppressor, NDRG1. This has led to commercialisation of DpC and the development of the international company, Oncochel Therapeutics LLC, USA and its Australian subsidiary, Oncochel Therapeutics Pty Ltd. Notably, DpC has entered multi-centre Phase I clinical trials for the treatment of advanced and resistant cancer.
Dr Elin Gray
School of Medical and Health Sciences
Edith Cowan University
Telephone: 6304 2756